Abstract
Introduction

1
Transcriptional dysregulation is required for tumor progression and drug resistance 2 acquisition. Many cancer driver genes are transcription factors (TFs). Notable examples 3 include TP53, the most commonly mutated tumor suppressor that controls cell growth 4 arrest (1) , and HIF1A, a key regulator of the adaptive response to hypoxia and 5 angiogenesis (2) . TFs are commonly dysregulated due to genomic alterations or aberrations 6 in their regulatory proteins. For example, TP53 activity can be suppressed through 7 amplification of its repressor MDM2(3) and HIF1A upregulation is often induced by loss-of-8 function mutations in VHL(4). Due to their role as downstream signalling effectors, aberrant 9 activities of any pathway protein may dysregulate TF activities, altering the expression of its 10 transcriptional targets or "regulon". Different from driver alterations in kinase-mediated 11 signalling cascades, where redundancy provides compensatory mechanisms, aberrant 12 transcriptional regulators have been argued to be harder to circumvent by secondary 13 genomic alterations(5). Consequently, TFs have been proposed as key nodal oncogenic 14 drivers and their activity patterns used to characterise genomic aberrations in cancer(6,7) or 15 their influence on a patient's prognosis(8). 16 Recently, the Genomics of Drug Sensitivity in Cancer (GDSC)(9,10), Cancer Therapeutics 17
Response Portal (CTRP)(11) and Cancer Cell Line Encyclopedia (CCLE) (12) have 18 generated large-scale public pharmacogenomic datasets spanning multiple molecular data 19 types across hundreds of cancer cell lines. These datasets enabled the identification of 20 genomic, transcriptomic and epigenomic markers of drug sensitivity (9, 10, 12) and have 21 uncovered a complex network of genomic alterations interacting with sensitivity to hundreds 22 of drugs. The challenge is now to dissect the underlying molecular mechanisms regulating 23 drug response, for which novel and more systemic functional approaches are needed. 24
Here we used TF regulatory activities as sensors of pathway dysregulation. Assuming that 25 the activity of a TF can be estimated from the mRNA levels of its direct target genes, defined 26
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Results
1
TF activities estimation
2 First, we assembled a collection of basal transcriptional profiles of immortalised human 3 cancer cell lines and primary tumors ( Figure 1A ). For cancer cell lines, we newly derived 4 RNA-seq data from 448 samples, that we complemented with RNA-seq profiles from 934 5 and 622 cell lines, respectively from the CCLE (12) and Klijn et al(14) . This yielded a total of 6 1,362 unique cancer cell lines, of which 1,056 are in COSMIC(13) ( Table S1A ). To minimise 7 technical biases, we derived raw counts using a common pipeline. For primary tumors, we 8 downloaded RNA-seq raw counts for 9,250 TCGA primary tumors and 741 normal 9 samples (16) . Cell lines and TCGA samples were processed and normalised separately. 10
11
To define the TF regulons (i.e. sets of genes whose transcription is regulated by a given TF), 12 we collected 15,211 TF-targets interactions appearing in at least 2 publicly available 13 resources (hereafter Consensus TF Regulons, CTFR; Figures 1B and S1A-B; Table S2 ). To 14 ensure a minimum signal when we compute the TF activities, we removed targets regulated 15 by more than 10 TFs and TFs with less than 3 targets in the expression matrix. The final 16
CTFRs consisted of 7,445 targets for 127 TFs, with 111 targets per TF on average ( Figure  17 S1C). Pairwise overlap between regulons was low (average Jaccard Similarity 18 Coefficient=0.0044, Figure S1D ), indicating negligible levels of redundancy between CTFRs. 19 20 Next, we normalised the transcriptomic data gene-wisely to estimate relative levels of basal 21 activity of each CTFR in each sample using the aREA algorithm(6). Cell lines and TCGA 22 samples (tumor+normal) were analysed separately ( Figure 1C ; Tables S3A-B) . Normalised 23 enrichment scores (NES) ( Figure S2A -D) were used as estimates of CTFR activity relative to 24 the background population (hereafter simplified as 'TF activities'). Subsampling analysis 25 revealed that activity estimates were robust in populations with n≥20 ( Figure S2E) . 26 1 We evaluated the TF activity estimations using independent benchmark data derived from 2 an essentiality screening (17) , and CNA and WES data in cell lines (Supplementary  3 Methods). Moreover, we investigated the inclusion of methylation data as a means to refine 4
CTFRs on a cell line-basis excluding from the regulons those targets with hypermethylated 5 promoters, not observing significant performance improvements (Supplementary File,  6 Figures S3-S4). Finally, we compared the activities derived from the CTFRs against those 7 derived from reverse-engineered regulons proposed in (6), observing slightly better 8 performances for CTFRs (Supplementary File, Figures S3-S6 ). Hence, we selected CTFRs-9 based estimations (without including promoter methylation information) for our downstream 10 analysis. 11
TF activities across primary tumors and cell lines
12
To obtain a global picture of TFs operating in primary tumors, we studied how TF activities 13 distribute across TCGA samples. Differential activity analysis of normal versus tumor 14 samples revealed groups of TFs consistently activated or repressed across the 14 tumor 15 types with matched normal samples. While most TF regulons decrease their activity, a small 16 subset undergoes a recurrent increase across tumor types (Figure 2A ), including oncogenic 17 regulators of cell cycle (MYC, MAX, E2F family members, FOS and FOXM1), tumor invasion 18 and angiogenesis (ELK1 and ETS1) (20) . 19 20 Next, we compared the TF profiles between cancer types. First, we summarised sample-21 level activities into cancer-level activities. For each TF, we ranked the samples based on TF 22 activity and quantified the enrichment of each cancer-type at the top of the ranks using the 23 aREA algorithm ( Figure S7A Cancer Protein Atlas v15(21)) showed that our approach captures 11 out of 12 TFs 7 operating preferentially in specific tissues in primary tumors ( Figure 2D ) such ESR1 and 8 FOXA1 in BRCA or MITF in SKCM. Note that for ZEB1, a transcriptional repressor involved 9 in epithelial-to-mesenchymal transition (EMT)(22), higher protein activities correspond to a 10 downregulation of the regulon. Importantly, these tendencies are maintained in the cell lines 11 with the exception of AR, where 4 out of 6 prostate cell lines display AR-independent 12 proliferation (Table S1C ). Taken together, these results show that our approach captures 13 expected activity patterns of known cancer-specific TFs. 14
TF activities dissect mutant-specific aberrations
15
Previous studies demonstrated that different mutations in the same protein could cause a 16 continuum of effects, ranging from neutrality to a significant functional impact(23). We thus 17 set-out to characterise the effect of mutations occurring in TFs on their own activity. As proof 18 of concept, we focused on TP53 due to its high mutation frequency and heterogeneity. We 19 curated TP53 mutations according to specific mutations, hotspots, protein consequence, 20 zygosity (in cell lines), affected domain, PTM or structural property and previously proposed 21 mutation stratifiers(24) (Table S4A ). Subsequently, we compared predicted TP53 activities of 22 each TP53 mutation group with wild-type samples ( Figure 3A ). To avoid confounding effects 23 due to the use of different samples and tumor types, we regressed-out the tissue lineage 24 from the TF activity profiles through linear modelling. Our results indicated that all TP53 25 mutation groups significantly affecting TP53 transcriptional activity decreased it ( Figure S8 ; 26 heterozygous mutations ( Figure 3B ). Focusing on the most frequent mutational hotspots 1 revealed that R231X and R273C reached larger effect sizes than R248Q and R175H 2 substitutions in both primary tumors and cell lines. However, direct pairwise comparison 3 between mutants did not yield significant results alone. Importantly, these significant 4 changes in activity were correlated between primary tumors and cell lines (R 2 =0.551, 5 p=1.14×10 -8 , Figure 3C ). This suggests that transcriptional activity prediction may better 6 capture effect on TP53 activity than mutation alone. This is supported by comparison of 7 activity predictions with experimentally defined TP53 mutant yeast transactivation class from 8 the IARC TP53 Database(25)where each possible TP53 missense mutation is assigned to a 9 transactivation class -functional, partially or non-functional-according to its effects on the 10 transcription of 8 TP53-responsive promoters in yeast). Comparison between non-functional 11 and the other missense mutants showed a significant agreement with our predictions in cell 12 lines (one-tailed t-tests, p=0.00535) and, although marginally significant, in primary tumors 13 (p=0.0418). 14
Motivated by these results, we investigated systematically the effect of mutations in TFs on 16 their activity. To distinguish mutant-specific effects, these were studied individually. 17
Importantly, to consider non-recurrent yet potentially functional driver mutations, we also 18 grouped mutations that, although introducing different changes in different residues, could 19 affect protein function in a similar way (e.g. same structural region, interaction or post-20 translational modification site). We recovered 1,200 mutation groups in 122 TFs from 21 primary tumors (n≥3). Pancancer analysis in primary tumors identified 9 TFs that, when 22 mutated, exhibit a significant change in activity(FDR<5%; Figure 3D , Table S4C Closer examination of results revealed again differences in the effect of mutation types on 5 protein activity. In NFE2L2, a cytoprotective oncogene, missense mutations affecting 6 p.W24/p.D29 residues at the surface or at the KEAP1-interface (positions 77-82) are 7 associated with higher NFE2L2 activity, with NFE2L2 W24R/C mutations causing the strongest 8 increase( Figure 3E ). Mutations at the KEAP1-binding site were already proposed to be 9 positively selected to abolish NFE2L2 degradation(26). 10
Associations with known driver mutations
11
Next, we evaluated how mutations in any cancer driver genes, proposed in(27,28), could 12 impact TF activities. We grouped mutations in driver genes following the same strategy 13 described for TFs. This yielded 1,774 mutation groups (n ≥ 5) in 171 driver genes. 14 Systematic comparisons of TF activities in mutant against wild-type primary tumors yielded 15 3,565 driver mutation groups-TF associations involving 97 driver genes and 75 TFs 16 (FDR<5%, Figure 4A -B; Table S5A ). The same analysis in cell lines allowed us to study only 17 533 mutation groups, and rendered fewer associations (probably due to lower sample 18 number) that involved 36 interactions between 17 drivers and 25 TFs (FDR<5% , Table S5B ). To assess whether the detected associations represent plausible driver-TF regulatory 1 events, we extracted directed edges from literature-curated signalling networks from 2 OmniPath(31) and quantified shortest path lengths between every driver-gene/TF pair. 3
Enrichment analysis confirmed that significant driver-gene/TF associations tend to be closer 4 than non-significant associations ( Figure 4D ). Next, we investigated whether the predicted 5 effect of driver mutations on TF activities (association sign) agrees with the TF's role in 6 cancer. We classified TFs into 3 groups according to their role in cancer: (i) up-regulated in 7 cancer, if the TF displays significant greater activity in tumor than in normal samples or is a 8 known oncogene(27,28); (ii) down-regulated, if the TF function is repressed in tumor 9 samples or is a tumor suppressor; or (iii) neutral. Enrichment analysis revealed that positive 10 driver/TF interactions (i.e. potential TF-activating events) tend to involve cancer upregulated 11
TFs, in contrast, negative interactions are more prone to involve cancer downregulated TFs 12 ( Figure 4E ). Taken together, our results suggest that the identified associations point to 13 potential mechanisms of driver-mediated transcriptional dysregulation in cancer. with 251 drugs (95%) and 123 TFs (97%) implicated in at least one interaction (Table S6A) . were enriched for cytotoxic drugs and compounds targeting cytoskeleton, metabolism, DNA 1 replication, JNK-p38 and ERK-MAPK signalling (FET p<0.001, Figure 5B ; Table S6D ). 
associated with TFs classically upregulated in actively proliferating cells such as MYC, while 1 activity of tissue-specific TFs (such as MITF, REST or HNF4A) was associated with 2 resistance to these drugs ( Figure 5D ). 3
4
The strongest detected association involved TP53 and Nutlin-3a (regression coefficient 5 (coeff)=-0.57, p=x1.58×10 -30 , Figure 5E ). Nutlin-3a is an MDM2-inhibitor that blocks MDM2-6 mediated TP53 degradation. Our results agree with pharmacogenomic studies in that 7 samples with lower TP53 activities show lower sensitivity to MDM2-inhibition(9,10). Another 8 strong interaction was ZEB1 upregulation, an EMT marker, associated with resistance to 9 EGFR inhibitor Afatinib (coeff=-0.53, p=5.19×10 -15 ) and Gefitinib (coeff=-0.24, p=5.9×10 -7 ). 10 This is in agreement with a recent study in NSCLC describing ZEB1-mediated acquired 11 resistance to EGFR-inhibitors(34). 12
13
Cancer-specific analysis revealed fewer associations compared to the pancancer analysis, 14 probably due to reduced sample size ( Figure 5F ; Table S6E ). Still, we recovered 125 TF-15 drug associations (p<0.001, FDR<10%), most in lymphoma, the largest subpopulation. 
We showed before that the strongest TF-drug association detected involved the well-known 1 interaction between TP53 and Nutlin-3a. According to previous studies, samples with TP53 2 mutations are Nutlin3a-resistant(9,10), while our results suggest that samples with higher 3 TP53 activities are more sensitive. We reasoned that protein activities might complement 4 mutation-based markers to further improve the stratification of sensitive and nonsensitive cell 5 lines. To test this hypothesis, we used a Likelihood Ratio test (LR) to compare 6 pharmacogenomic models with and without including TF activities ( Figure 6A ). We confirmed 7 that TP53 activity was able to further identify sensitive cell lines among wild--type samples 8 including JUND in the model, among others (p=1.86×10 -11 , p=3.12×10 -11 and p=1.77×10 -8 ; 7
Trametinib, RDEA119 and AZD6244, respectively; Figure 6D ). JUND is a downstream 8 substrate in ERK-MAPK signalling(32). Our previous analysis already suggested JUND 9 activity be predictive of MEK-inhibition sensitivity alone. Here we show how JUND also 10 improves response prediction to MEK inhibitor AZD6244 within HRAS mutant pancancer 11 samples (p=1.21×10 -7 ). Taken together, our results suggest that JUND regulon expression 12 may be used as a sensor of ERK-MAPK pathway activity and vulnerability to MEK-inhibition. CAN-17-1679 of TFs. Pertinent examples are loss-of-function TP53 missense mutants which, while 1 abundantly present at mRNA and protein level, are unable to regulate the expression of its 2 canonical targets. Finally, the inference of such condition-specific networks requires a prior 3 classification of samples, which may not be trivial for heterogeneous cancer cell line panels. 4
An alternative could combine CTFRs with network inference approaches(50). 5 Nonetheless, our TF predictions based on CTFRs agree with independent essentiality 6 screenings and genomic data, and mimic changes in transactivation potential observed in 7 mutagenesis studies. Importantly, CTFRs are able to reproduce known pharmacogenomic 8 interactions while inferred regulons fail to do so. However, it is worth mentioning that our 9 strategy to retrieve CTFRs may favour well-studied TFs, whose targets are thoroughly 10 characterised, thus resulting in biased performances. Further refinement of the approaches 11 to define TF regulons activity in cancer should enable to find further pharmacogenomic 12 interactions, novel markers and therapeutic opportunities. 13
Briefly, our results demonstrate that TF activity profiles derived from CTFRs can be used to 14 characterise genomic alterations and drug response in cancer patients, proposing these as 15 promising complementary therapeutic markers. The proposed approach may have strong 16 implications in the refinement of personalised treatment methodologies. We envision that 17 with the increase in the coverage and quality of the CTFRs, the proposed strategy will 18 become instrumental to interpret transcriptional dysregulation in cancer and elucidate its 19 clinical implications. 20 
